Dopamine depletion and subcortical dysfunction disrupt cortical synchronization and metastability affecting cognitive
Linbo Wang1,2,3,4, Cheng Zhou5, Wei Cheng1,2,3,4,6
1Institute of Science and Technology for Brain-Inspired Intelligence, Fudan University, Shanghai, China.
Human Brain Mapping
|December 14, 2021
Summary
Subcortical dysfunction and dopamine loss in Parkinson's disease (PD) reduce cortical synchronization and affect cognition. Restoring dopamine improves brain activity, potentially aiding in dementia risk prediction.
Area of Science:
- Neuroscience
- Neurology
- Cognitive Science
Background:
- Parkinson's disease (PD) involves dopaminergic cell loss and subcortical atrophy, impacting brain function.
- The effect of these changes on cortical dynamics and cognitive performance in PD is not fully understood.
Purpose of the Study:
- To investigate how subcortical dysfunction influences cortical dynamics and cognition in Parkinson's disease.
- To explore the role of dopamine levels and subcortical structures in modulating these effects.
Main Methods:
- Resting-state fMRI was used to analyze spatiotemporal dynamics of phase interactions in 159 PD patients and 152 controls.
- Relationships between subcortical atrophy, connectivity, cortical synchronization/metastability, and cognition were assessed.
- PD patients were studied both ON and OFF dopamine replacement therapy.
Main Results:
- PD patients exhibited significantly decreased cortical synchronization and metastability.
- Dopamine replacement therapy increased cortical synchronization and metastability.
- Cortical synchronization and metastability in the dopamine-OFF state correlated with cognitive performance and mediated group differences.
- Thalamic volume and thalamocortical connectivity positively related to cortical synchronization in the dopamine-OFF state, mediating group differences.
Conclusions:
- Subcortical dysfunction and reduced dopamine levels decrease cortical synchronization and metastability in PD.
- These alterations in brain dynamics significantly affect cognitive performance.
- Findings suggest potential biomarkers for predicting dementia risk in PD patients.
Related Concept Videos
01:15Parkinson's Disease: Overview
814
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
814
01:24Parkinson's Disease: Treatment
436
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
436
01:37Neural Regulation
40.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
40.5K
01:29Drugs Affecting Neurotransmitter Synthesis
1.7K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.7K
01:26Alzheimer's Disease: Overview
732
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
732
01:27Psychosis: Pathophysiology of Schizophrenia and Other Psychotic Disorders
1.1K
Schizophrenia is a neurodevelopmental disorder whose origins are rooted in complex genetic components. Despite our burgeoning understanding, the pathophysiology of this disorder remains incompletely deciphered.
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
Researchers have identified genetic factors that increase susceptibility to schizophrenia, underscoring the intricate interplay between genetics and environment in disease development. At the core of schizophrenia's pathophysiology is excessive dopaminergic neurotransmission within...
1.1K